Acute Lymphoblastic Leukemia, Pediatric
Conditions
Keywords
Curcumin, Ain Shams University, Egypt, Acute Lymphoblastic Leukemia, Children
Brief summary
Assessment of of the biological effects of curcumin on microbiota in children with acute lymphoblastic leukemia
Detailed description
Assessment of the safety of curcumin, which is the most active constituent of the ground rhizome of the Curcuma longa plant, in children with acute lymphoblastic leukemia patients (ALL) in maintenance phase of chemotherapy through the assessment of the any reported adverse event (AE). And assessment of the curcumin effect on health by eliminating intestinal microflora dysbiosis
Interventions
DRUGCurcumin
Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement
DIETARY_SUPPLEMENTStandard of Care
As per institution protocol for Standard of nutritional Care
Sponsors
Ain Shams University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
Children aged from 1 year to 18 years Children with proven ALL diagnosed by bone marrow aspirate and immunephenotyping Patients in the maintenance phase week1
Exclusion criteria
Children with other maliganacies, Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including to sulfasalazine, warfarin, clopidogrel, aspirin, antacids, botanical treatments (ginger, feverfew, yellow clover, Salix species, Populus species, Betula species, and Gaultheria species), essential fatty acids (flax oil and fish oil).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the Safety of curcumin in pediatric patients with ALL. | 4 weeks | Percentage of patients who developed adverse event |
Countries
Egypt
Outcome results
None listed